http://venturebeat.com/2007/10/08/ipo-roundup-map-pharmas-mixed-reception-other-recent-filings/ News About Tech, Money and Innovation Thu, 26 Nov 2009 00:08:56 +0000 http://wordpress.org/?v=2.8.5 hourly 1 http://venturebeat.com/2007/10/08/ipo-roundup-map-pharmas-mixed-reception-other-recent-filings/comment-page-1/#comment-800189 Life-science briefing: Tuesday, March 25, 2008 » VentureBeat Tue, 25 Mar 2008 16:13:30 +0000 http://venturebeat.com/2007/10/08/ipo-roundup-map-pharmas-mixed-reception-other-recent-filings/#comment-800189 [...] startups working on similar technology include Emphasys Medical, Pulmonx and Broncus [...] [...] startups working on similar technology include Emphasys Medical, Pulmonx and Broncus [...]

]]> http://venturebeat.com/2007/10/08/ipo-roundup-map-pharmas-mixed-reception-other-recent-filings/comment-page-1/#comment-643652 VentureBeat » IPO roundup: Broncus Tech, Aegerion Pharma rides again, and more Tue, 20 Nov 2007 23:09:11 +0000 http://venturebeat.com/2007/10/08/ipo-roundup-map-pharmas-mixed-reception-other-recent-filings/#comment-643652 [...] previously written about Emphasys Medical, which has also filed for an IPO (see the third item here) and Pulmonx (see [...] [...] previously written about Emphasys Medical, which has also filed for an IPO (see the third item here) and Pulmonx (see [...]

]]> http://venturebeat.com/2007/10/08/ipo-roundup-map-pharmas-mixed-reception-other-recent-filings/comment-page-1/#comment-643666 VentureBeat » IPO roundup: Broncus Tech, Aegerion Pharma rides again, and more Tue, 20 Nov 2007 23:09:11 +0000 http://venturebeat.com/2007/10/08/ipo-roundup-map-pharmas-mixed-reception-other-recent-filings/#comment-643666 [...] previously written about Emphasys Medical, which has also filed for an IPO (see the third item here) and Pulmonx (see [...] [...] previously written about Emphasys Medical, which has also filed for an IPO (see the third item here) and Pulmonx (see [...]

]]> http://venturebeat.com/2007/10/08/ipo-roundup-map-pharmas-mixed-reception-other-recent-filings/comment-page-1/#comment-599986 VentureBeat » IPO roundup: Bioheart, Merrion Pharma in limbo; Reliant vs. Reliant road shows; upcoming offerings Mon, 29 Oct 2007 00:39:52 +0000 http://venturebeat.com/2007/10/08/ipo-roundup-map-pharmas-mixed-reception-other-recent-filings/#comment-599986 [...] week and is now also scheduled on a “day-to-day” basis. (Our coverage of the company is here.) Of course, even Merrion’s situation looks good compared to Cumberland Pharmaceuticals, [...] [...] week and is now also scheduled on a “day-to-day” basis. (Our coverage of the company is here.) Of course, even Merrion’s situation looks good compared to Cumberland Pharmaceuticals, [...]

]]> http://venturebeat.com/2007/10/08/ipo-roundup-map-pharmas-mixed-reception-other-recent-filings/comment-page-1/#comment-568570 Skin Care » Blog Archive » IPO roundup: MAP Pharma’s mixed reception, other recent filings Mon, 08 Oct 2007 20:19:35 +0000 http://venturebeat.com/2007/10/08/ipo-roundup-map-pharmas-mixed-reception-other-recent-filings/#comment-568570 [...] Read this great post here [...] [...] Read this great post here [...]

]]> http://venturebeat.com/2007/10/08/ipo-roundup-map-pharmas-mixed-reception-other-recent-filings/comment-page-1/#comment-568416 VentureBeat » Life sciences briefing: Monday, Oct. 8, 2007 Mon, 08 Oct 2007 17:56:37 +0000 http://venturebeat.com/2007/10/08/ipo-roundup-map-pharmas-mixed-reception-other-recent-filings/#comment-568416 [...] Anacor is developing a new class of antibiotics, antifungal drugs and anti-inflammatories based on the novel properties of boron, an element that doesn’t feature largely in traditional pharmaceuticals. Its leading candidates target a fungal infection called onychomycosis and the autoimmune skin condition psoriasis. The company filed for a $58 million IPO in August; see our coverage here. [...] [...] Anacor is developing a new class of antibiotics, antifungal drugs and anti-inflammatories based on the novel properties of boron, an element that doesn’t feature largely in traditional pharmaceuticals. Its leading candidates target a fungal infection called onychomycosis and the autoimmune skin condition psoriasis. The company filed for a $58 million IPO in August; see our coverage here. [...]

]]> http://venturebeat.com/2007/10/08/ipo-roundup-map-pharmas-mixed-reception-other-recent-filings/comment-page-1/#comment-568318 VentureBeat » MAP Pharma’s mixed IPO reception Mon, 08 Oct 2007 16:22:59 +0000 http://venturebeat.com/2007/10/08/ipo-roundup-map-pharmas-mixed-reception-other-recent-filings/#comment-568318 [...] our story about the IPO of this Mountain View, Calif., specialty pharma at VentureBeat Life Sciences. Tagged [...] [...] our story about the IPO of this Mountain View, Calif., specialty pharma at VentureBeat Life Sciences. Tagged [...]

]]>